Arbutus Biopharma Corp (I9DN)

2.111
-0.046(-2.16%)
  • Volume:
    524
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    2.111 - 2.115
  • Type:Equity
  • Market:Germany
  • ISIN:CA03879J1003
  • WKN:A14XMD

I9DN Overview

Prev. Close
2.157
Day's Range
2.111-2.115
Revenue
18.87M
Open
2.115
52 wk Range
1.837-5.602
EPS
-1.71
Volume
524
Market Cap
336.66M
Dividend (Yield)
0.00
(0.00%)
Average Vol. (3m)
1,169
P/E Ratio
-
Beta
0.24
1-Year Change
3.55%
Shares Outstanding
148,728,237
Next Earnings Date
-
What is your sentiment on Arbutus Biopharma?
or
Market is currently closed. Voting is open during market hours.

Arbutus Biopharma Corp News

Arbutus Biopharma Corp Analysis

Arbutus Biopharma Corp Company Profile

Arbutus Biopharma Corp Company Profile

Employees
86

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • today we go to the moon
    1
    • when will this stock turn around? anyone know why it is dropping?
      0
      • this is pure manipulation how you know easy think about this Moderna is down almost 10% today on this news since yesterday is going down basically because ABUS will get royalties on their pattern and this happens the winner of the history also down 10% unbelievable
        1
        • yeah Aket I think we went to the SUN instead of Mars crazy 🤪 drop like always hedges playing with the market they building PUTs and collecting
          0
          • Thank to them i bought more 🥴🤌🏾
            0
          • wow nice I just double my position on this another 10k lets see at least volume still increasing and thats good 👍
            0
        • We go to Mars 🚀🚀🚀
          1
          • I believe so, we had buyers yesterday all the way to 6-6.50 so it has plenty of room to the upside.
            0
          • If ABUS don’t make a annonce about sueing MNR, it’s probably means that they are talking each other for a deal
            0
        • interesting reading also here: https://www.tipranks.com/news/blurbs/jmp-securities-believes-arbutus-biopharma-abus-wont-stop-here?mod=mw_quote_news
          0
          • I hear it is 10% Moderna has to pay to ABUS. Give or take, but it is a looooot of money
            0
            • Where did you hear that ?
              0
            • Cant name the sources. As I said give or take. The roumer is around
              0
          • make target lies on 20-23
            0
            • we should be reaching 8s tomorrow with this much volume plus even though the market over reacting to the new Omicron bsh this could easily be in the 20s by next week ofcourse when rumors comes out of an agreement between Moderna and ABUS this will fly on my calculations Moderna made on this pattern about 72 billions so what ever % they could settle will send this to the moon
              1
              • We will buy more 🤌🏾
                0
              • Estas seguro de que saldrá de los $4.30?
                1
              • One thing is clear, they will make tons of moooonneeeyyy and Modern will have to settle for ***billions
                0
            • Moderna will buy soon, be ready guys 😛😛😛🚀🚀🚀
              0
              • wow that's the best Idea ever but ABUS are not stupid because the billions of dollars that they need to pay in royalties is easy about 10 billion and ABUS market cap is only 600 million 😉
                0
              • they will settl for X amount and get royalties from every vaccine sold. So ******yea this will double, no doubt in that
                0